BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 9871428)

  • 1. A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 alpha-reductase inhibitors GI198745 and finasteride.
    Gisleskog PO; Hermann D; Hammarlund-Udenaes M; Karlsson MO
    Clin Pharmacol Ther; 1998 Dec; 64(6):636-47. PubMed ID: 9871428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
    Lazier CB; Thomas LN; Douglas RC; Vessey JP; Rittmaster RS
    Prostate; 2004 Feb; 58(2):130-44. PubMed ID: 14716738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of dutasteride on reduction of plasma DHT following finasteride therapy in patients with benign prostatic hyperplasia].
    Botto H; Lan O; Poulain JE; Comenducci A
    Prog Urol; 2005 Dec; 15(6):1090-5. PubMed ID: 16429658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetic analysis of human steroid 5 alpha reductase type II: comparison of finasteride and dutasteride.
    Makridakis N; Reichardt JK
    J Mol Endocrinol; 2005 Jun; 34(3):617-23. PubMed ID: 15956333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MK-386, an inhibitor of 5alpha-reductase type 1, reduces dihydrotestosterone concentrations in serum and sebum without affecting dihydrotestosterone concentrations in semen.
    Schwartz JI; Tanaka WK; Wang DZ; Ebel DL; Geissler LA; Dallob A; Hafkin B; Gertz BJ
    J Clin Endocrinol Metab; 1997 May; 82(5):1373-7. PubMed ID: 9141518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
    Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
    Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic parameters and mechanisms of inhibition of rat type 1 and 2 steroid 5alpha-reductases: determinants for different in vivo activities of GI198745 and finasteride in the rat.
    Stuart JD; Lee FW; Simpson Noel D; Kadwell SH; Overton LK; Hoffman CR; Kost TA; Tippin TK; Yeager RL; Batchelor KW; Bramson HN
    Biochem Pharmacol; 2001 Oct; 62(7):933-42. PubMed ID: 11543729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Epididymis in an experimental model of DHT deficiency: immunolocalization of ERalpha and ERbeta in rat epididymal epithelial cells. In vivo and in vitro studies].
    Kolasa A
    Ann Acad Med Stetin; 2006; 52(2):13-21; discussion 21. PubMed ID: 17633123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic modeling of finasteride, a 5 alpha-reductase inhibitor.
    Ko HC; Jusko WJ
    Pharmacotherapy; 1995; 15(4):509-11. PubMed ID: 7479205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5 alpha-reductase inhibition by a new synthetic steroid (PM-9) in cultures of Penicillium crustosum.
    Cabeza M; Quiroz A; Bratoeff E; García G; Ramírez E; Flores E
    Proc West Pharmacol Soc; 2002; 45():164-5. PubMed ID: 12434569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Finasteride for benign prostatic hyperplasia.
    Hasinski S; Miller JL; Rose LI
    Am Fam Physician; 1992 Nov; 46(5):1511-4. PubMed ID: 1279965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride.
    Olsen EA; Hordinsky M; Whiting D; Stough D; Hobbs S; Ellis ML; Wilson T; Rittmaster RS;
    J Am Acad Dermatol; 2006 Dec; 55(6):1014-23. PubMed ID: 17110217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia.
    Drake L; Hordinsky M; Fiedler V; Swinehart J; Unger WP; Cotterill PC; Thiboutot DM; Lowe N; Jacobson C; Whiting D; Stieglitz S; Kraus SJ; Griffin EI; Weiss D; Carrington P; Gencheff C; Cole GW; Pariser DM; Epstein ES; Tanaka W; Dallob A; Vandormael K; Geissler L; Waldstreicher J
    J Am Acad Dermatol; 1999 Oct; 41(4):550-4. PubMed ID: 10495374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Actions of 5alpha-reductase inhibitors on the epididymis.
    Robaire B; Henderson NA
    Mol Cell Endocrinol; 2006 May; 250(1-2):190-5. PubMed ID: 16476520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of androgens in the scalp hair and plasma of patients with male-pattern baldness before and after finasteride administration.
    Ryu HK; Kim KM; Yoo EA; Sim WY; Chung BC
    Br J Dermatol; 2006 Apr; 154(4):730-4. PubMed ID: 16536818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR.
    Bramson HN; Hermann D; Batchelor KW; Lee FW; James MK; Frye SV
    J Pharmacol Exp Ther; 1997 Sep; 282(3):1496-502. PubMed ID: 9316864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of MK-386, a novel inhibitor of type 1 5 alpha-reductase, alone and in combination with finasteride, on serum dihydrotestosterone concentrations in men.
    Schwartz JI; Van Hecken A; De Schepper PJ; De Lepeleire I; Lasseter KC; Shamblen EC; Winchell GA; Constanzer ML; Chavez CM; Wang DZ; Ebel DL; Justice SJ; Gertz BJ
    J Clin Endocrinol Metab; 1996 Aug; 81(8):2942-7. PubMed ID: 8768856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate.
    Span PN; Völler MC; Smals AG; Sweep FG; Schalken JA; Feneley MR; Kirby RS
    J Urol; 1999 Jan; 161(1):332-7. PubMed ID: 10037433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral testosterone in oil: pharmacokinetic effects of 5alpha reduction by finasteride or dutasteride and food intake in men.
    Amory JK; Page ST; Bremner WJ
    J Androl; 2006; 27(1):72-8. PubMed ID: 16400081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
    Bartsch G; Rittmaster RS; Klocker H
    World J Urol; 2002 Apr; 19(6):413-25. PubMed ID: 12022710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.